AzTrials
AzTrials

Liver TransplantationNCT06162260

Unplanned ICU Readmission for Pediatric Liver Transplantation

An observational study of Liver Transplantation, run by RenJi Hospital.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To explore the risk factors of unplanned return to Intensive Care Unit (ICU) in pediatric liver transplant recipients, and to provide data support for the transfer of pediatric liver transplant recipients from ICU after surgery, so as to avoid unplanned ICU return and reduce the mortality of patients during… Read more about this study

Who is it for?
Ages 1 month to 18 years
Conditions the study is for
Liver Transplantation
What is being tested?
ICU readmission
Type of treatment
Surgery or procedure
How many people
1,575 participants
Where
No sites listed yet
Study dates
1 Dec 2023to 28 Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Children who underwent liver transplantation at Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from Jan 1, 2018 to Dec 31, 2021.

Who may be able to join

  • (1) Liver transplantation was performed from January, 2018 to December, 31, 2021.21;
  • (2) Age < 18 years;
  • (3) The patient was admitted to ICU for the first time due to postoperative monitoring after liver transplantation;
  • (4) Survival on first transfer from ICU.

Who cannot join

  • (1) Death during ICU stay after liver transplantation;
  • (2) non-first-time recipients of liver transplantation;
  • (3) Patients with complex conditions who were transferred to ICU for life support (such as mechanical ventilation, CRRT, etc.) before operation;
  • (4) Patients admitted to ICU by appointment for surgical reasons.
  • (5) Patients forcibly transferred from ICU.

About this study

Official title: Analyse Des Facteurs de Risque Pour la réintégration Non planifiée Post-opératoire de Patients transplantés du Foie Chez l'Enfant

To explore the risk factors of unplanned return to Intensive Care Unit (ICU) in pediatric liver transplant recipients, and to provide data support for the transfer of pediatric liver transplant recipients from ICU after surgery, so as to avoid unplanned ICU return and reduce the mortality of patients during hospitalization.

Read the detailed description

In recent years, with the progress of medical level, pediatric liver transplantation has been used in a variety of pediatric end-stage liver diseases, such as intrahepatic cholestasis, metabolic diseases, acute liver failure, liver tumors and other diseases. It is the only effective way to treat pediatric end-stage liver diseases. The maturity of surgical techniques and the application of immunosuppressants have greatly improved the overall survival rate of children after liver transplantation. In some developed countries, the 1-year and 5-year survival rates of children after liver transplantation can reach more than 80%. Pediatric liver transplantation is difficult, and the postoperative condition is complicated and changes rapidly, which requires Intensive Care Unit (ICU) for intensive monitoring. However, unplanned reentry to the ICU occurs in some pediatric liver transplant recipients who have been transferred out of the ICU and need to be transferred again because of a change in their condition. Unplanned ICU return leads to increased mortality, longer hospital stay, and higher hospital costs. For example, Rosenberg et al. [5] reported that the comprehensive ICU re-entry rate was 4-14% (average 7%), the average length of stay was more than twice that of non-re-entrants, and the mortality rate was 2-10 times that of non-re-entrants. Kramer et al. [8] analyzed 229375 patients in 97 intensive care units from 2001 to 2009, and the re-entry rate was 6.1%. The average length of stay of the re-entry patients was 2.5 times higher than that of the non-re-entry patients, and the mortality rate was 4 times higher than that of the non-re-entry patients. Therefore, unplanned ICU re-entry is a rare but serious event, which has important clinical significance for the study of unplanned ICU re-entry.

There are significant differences in ICU re-entry rates among liver transplant recipients in different studies. Young Gon Son et al. reported that 5.8% (68 patients /1181 patients) of the enrolled patients underwent ICU re-entry after liver transplantation. A case-control study at a Canadian medical center showed that 14% of 369 patients who received liver transplants at the center between 2005 and 2012 had ICU re-entry; They had a longer first hospital stay (P<0.001) and a lower cumulative survival rate of 1 month to 2 years (P<0.001). The study by Mark et al. showed that ICU re-entry occurred in 34% of 167 liver transplant recipients. Several studies of risk factors for ICU return after liver transplantation have also shown mixed results. For example, Levy et al. showed that older age and more intraoperative blood transfusion in liver transplant recipients were positively associated with ICU return. Filipe et al. showed that more than 20 breaths per minute at ICU discharge after liver transplantation was an independent risk factor for ICU return during the same hospitalization. At present, studies on ICU re-entry rate and risk factors after liver transplantation mostly focus on adult liver transplant recipients. There are no reports on risk factors for ICU return after liver transplantation in children. Some reports of PICU's return were found. For example, Angela S statistically analyzed 117,923 children admitted to 73 PICUs from 2005 to 2008. The ICU re-entry rate was 3.7%, of which 38%(1.4%) occurred early (ICU re-entry within 48 hours). Patient characteristics strongly associated with an increased risk of early readmission included age < 6 months, acute respiratory and renal disease, and underlying chronic conditions such as liver disease, bone marrow transplantation, and airway stenosis. Afrothite Kotsakis's study showed that younger age, lower body weight, longer first ICU stay, and non-target time transfer (06:00-11:59) were among the factors affecting children's ICU return. Can these conditions and risk factors for PICU re-entry and ICU re-entry in adult liver transplant recipients be applied to analyze ICU re-entry in pediatric liver transplant recipients? We don't know. Because there is a significant physiological difference between adults and children, liver transplantation is difficult to apply PICU reentry cause analysis due to the difficulty of operation and the uniqueness of immunosuppressive therapy. In other words, risk factors for postoperative ICU return in pediatric liver transplant recipients may differ from those in adult liver transplant recipients and other children. Therefore, a separate analysis of risk factors for unplanned ICU return after liver transplantation in children is necessary.

Being tested
ICU readmission
Keywords
readdmission;ICU;transplantation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ICU readmissionProcedure or surgery

    Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.

Study groups in NCT06162260
Study groupRoleWhat they receive
observation group(1) Liver transplantation was performed between January 1, 2019 and December 31, 2019; (2) Age < 18 years; (3) The patient was admitted to ICU for the first time due to postoperative monitoring after liver transplantation; (4) Survival on first transfer from ICU.
Receives: Procedure: ICU readmission
matched group(1) Liver transplantation was performed between January 1, 2019 and December 31, 2019; (2) Age < 18 years; (3) The patient was admitted to ICU for the first time due to postoperative monitoring after liver transplantation; (4) survive the first transfer from ICU; (5) No ICU re-entry occurred in the same hospitalization period after liver transplantation.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Unplanned return to the ICU

    ICU re-entry occurred within the same hospital cycle after the first ICU transfer after liver transplantation

    Measured: 01/01/2018-31/12/2021

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Dec 2023
  2. Study start1 Dec 2023 (estimated)
  3. Primary completion29 Nov 2024 (estimated)
  4. Study completion28 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
1,575 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06162260
Sponsor's protocol ID
gaoleiqing
Status last verified
Dec 2023
First submitted
1 Dec 2023
Last updated
8 Dec 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Liver Transplantation, run by RenJi Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Unplanned return to the ICU (time frame: 01/01/2018-31/12/2021). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in